次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

医薬品安全性監視(ファーマコビジランス)の世界市場および業界分析2014-2024年

Pharmacovigilance and Related Developments: Industry and Market Analysis 2014-2024

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2014年4月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文146ページになります。
商品コード:VGN216

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
Visiogain社では医薬品安全性監視(ファーマコビジランス)の世界市場は2018年に106億ドルに達し、2024年にかけて拡大し続けると予測しています。2014年以後、アウトソース運用の増加が見込まれ、製薬会社、CRO、その他市場関係者の利便性に資するでしょう。当レポートでは同市場の2024年に至る市場予測、詳細なセグメント別予測分析に加え、市場動向、リーディング企業情報などを概略以下の構成でお届けしています

【レポート構成概要】
・医薬品安全性監視(ファーマコビジランス)の世界市場予測2014-2024年
・全146ページ、71個のデータ表、グラフ類で分析定量化
・業界専門家オピニオンインタビュー:
- Nina Lahanis, Vice President of Marketing and Business Development, Drug Safety Alliance, USA
- Dr Angela van der Salm, Director of Pharmacovigilance, DADA Consultancy, Netherlands
- Mark Bartlett, Co-Founder and Managing Director, Geneix, UK

・主要12ヶ国、国別市場予測2014-2024年
• 米国VGN216_Pharmacovigilance and Related Developments Industry and Market Analysis 2014-2024 Cover.jpgレポート表紙
• 日本
• ドイツ、フランス、英国、イタリア、スペイン (EU5)、およびEU
• ブラジル、ロシア、インド、中国、韓国

・市場動向分析
• 薬物有害反応(ADRs)報告システム
• 市販後調査へと向かう医薬品承認
• ソーシャルメディアを活用した安全性監視、ビッグデータの可能性
• より柔軟な医薬品承認プロセスにつながるデータ収集とコミュニケーションの改善。販売承認の過程の変化
• 国および国際機関の政策。医薬品安全性監視における規制当局の役割と今後
• アウトソース受託企業、ソフトウェアベンダー、規制コンサルタント、CRO
• 医薬品研究開発全体の予算支出予測、その医薬品監視への影響
• アメリカ食品医薬品局(FDA)と欧州医薬品庁(EMA)の連携
• 薬理ゲノム学とバイオマーカーのアプリケーション
• 電子医療記録システムの使用

・リーディング企業プロフィール
• Pfizer
• Johnson & Johnson
• GlaxoSmithKline (GSK)
• Sanofi
• Novartis
• AstraZeneca
• Eli Lilly.

・スペシャリスト企業情報
• Quintiles
• Covance
• Parexel
• Accenture
• Cognizant Technology Solutions
• Infosys
• Oracle

Visiongain is a trading partner with the US Federal Government
【レポート詳細目次は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Pharmacovigilance and Related Developments: Industry and Market Analysis 2014-2024

Table of Contents

1. Executive Summary

1.1 Introduction to This New Study
1.2 Chapter Contents – What You Find in That Work
1.3 Research and Analysis Methods

2. Introduction to Pharmacovigilance

2.1 Adverse Drug Reactions
2.1.1 ADRs are Not Side Effects
2.1.2 Terminology in the US and EU
2.2 Never Events
2.3 Safety Signals, What They Mean and How to Identify Them
2.4 Pharmacovigilance, a Historical Perspective
2.4.1 Thalidomide
2.4.2 Eraldin
2.4.3 Vioxx
2.4.4 Avandia
2.5 Drug Safety Monitoring in Clinical Trials
2.5.1 Phase I Clinical Trials
2.5.2 Phase II Clinical Trials
2.5.3 Phase III Clinical Trials
2.5.3.1 Limitations of Phase I-III Trials
2.6 Phase IV – Post-Marketing Studies
2.7 Pharmacovigilance in the Pharmaceutical Industry
2.8 The Pharmacovigilance Practices of the Leading Pharmaceutical Companies
2.8.1 Pfizer
2.8.2 Johnson & Johnson
2.8.3 GlaxoSmithKline
2.8.4 Sanofi
2.8.5 Novartis
2.8.6 AstraZeneca
2.8.7 Roche
2.8.8 Abbott Laboratories
2.8.9 Eli Lilly
2.8.10 Bristol-Myers Squibb

3. Pharmacovigilance: World Market, 2014-2024

3.1 The WHO Programme for International Drug Monitoring
3.1.1 Data Collection at the Uppsala Monitoring Centre
3.1.2 VigiBase – The Global Drug Safety Repository
3.2 Pharmacovigilance in Research and Development: Forecast 2013-2024
3.3 Global Pharmacovigilance Market Forecast 2013-2024
3.4 Pharmacovigilance Market: Drivers and Restraints 2014-2024
3.4.1 Volume of ADRs Set to Rise
3.4.2 Reduced Pre-Market Safety Data – Focus Shifts to Post-Approval Monitoring
3.4.3 New EU Regulations Will Demand a Revamp of Entire Pharmacovigilance Protocols
3.4.4 Active Drug Safety Monitoring Set to Increase
3.4.5 Lack of Harmonisation Leads to Cross Border Difficulties
3.4.6 Transparency is Crucial in the Future of Pharmacovigilance
3.4.7 Direct Consumer Reports Lack Quality to Detect Causal Safety Signals
3.4.8 Merged Companies Spend Less on Pharmacovigilance

4. Leading National and Regional Markets, 2014-2024

4.1 Regional Breakdown of the World Pharmacovigilance Market, 2013
4.2 World Pharmacovigilance Market: Regional Forecast 2014-2024
4.2.1 How Will Regional Market Shares Change to Between 2013 and 2024?
4.3 The US Pharmacovigilance Market, 2014-2024
4.3.1 Criticism of the FDA
4.3.2 Periodic and Spontaneous Safety Reports
4.3.3 ADR Metrics for the US Market, 2003-2012
4.3.4 US Market Forecast, 2014-2024
4.4 The European Pharmacovigilance Market, 2014-2024
4.4.1 New EU Regulations Making the Biggest Impact for Twenty Years
4.4.2 Quality at the Heart of Safety Monitoring
4.4.3 Pharmacovigilance System Master File – Added Complexity in the Short Term
4.4.4 ADR Reporting and Safety Signal Detection
4.4.5 EU Market Forecast, 2014-2024
4.4.6 ADR Metrics for the European Union, 2012
4.5 The German Pharmacovigilance Market, 2014-2024
4.5.1 German Market Forecast, 2014-2024
4.6 The French Pharmacovigilance Market, 2014-2024
4.6.1 French Market Forecast, 2014-2024
4.7 The UK Pharmacovigilance Market, 2014-2024
4.7.1 UK Market Forecast, 2014-2024
4.8 The Italian Pharmacovigilance Market 2014-2024
4.8.1 Italian Market Forecast, 2014-2024
4.9 The Spanish Pharmacovigilance Market 2014-2024
4.9.1 Spanish Market Forecast, 2014-2024
4.10 Japanese Pharmacovigilance Market 2014-2024
4.10.1 Early Stage Drug Monitoring
4.10.2 Expedited and Periodic Safety Reports
4.10.3 Japanese Market Forecast, 2014-2024
4.11 Pharmacovigilance in the BRIC Nations, 2014-2024
4.12 The Chinese Pharmacovigilance Market, 2014-2024
4.12.1 ADR Metrics for the Chinese Market 2003-2012
4.12.2 Chinese Market Forecast, 2014-2024
4.13 The Brazilian Pharmacovigilance Market, 2014-2024
4.13.1 Brazilian Market Forecast, 2014-2024
4.14 The Russian Pharmacovigilance Market, 2014-2024
4.14.1 Russian Market Forecast, 2014-2024
4.15 The Indian Pharmacovigilance Market, 2014-2024
4.15.1 ADR Metrics for Indian Market 2010-2013
4.15.2 Indian Market Forecast 2014-2024
4.16 The South Korean Pharmacovigilance Market, 2014-2024
4.16.1 ADR Metrics for South Korea, 2003-2012
4.16.2 South Korean Market Forecast, 2014-2024

5. Leading Pharmacovigilance Companies, 2014

5.1 Business Process Outsourcing Firms
5.1.1 Accenture – The Leading Business Process Outsourcing Firm
5.1.2 Cognizant Technology Solutions
5.1.3 Tata Consultancy Services
5.1.4 Capgemini
5.1.5 Tech Mahindra
5.1.6 Infosys
5.1.7 Wipro Limited
5.1.8 HCL Technologies
5.1.9 iGATE Corporation
5.2 Contract Research Organisations (CROs)
5.2.1 Quintiles Transnational
5.2.2 Covance
5.2.3 Parexel
5.2.4 ICON
5.2.5 inVentiv Health
5.2.6 PRA International
5.2.7 PharSafer
5.3 Software Providers
5.3.1 Oracle
5.3.2 ArisGlobal
5.4 Other Outsourcing Companies
5.4.1 Drug Safety Alliance
5.4.2 Foresight Group International
5.4.3 TAKE Solutions
5.5 Other Pharmacovigilance Service Providers

6. Qualitative Analysis of the Pharmacovigilance Market, 2014-2024

6.1 SWOT Analysis of the Pharmacovigilance Market
6.2 STEP Analysis of Factors Affect the Pharmacovigilance Market
6.3 Social Forces
6.4 Technological Forces
6.5 Economic Forces
6.6 Political Forces
6.7 Increased Focus on Pharmacovigilance in the Emerging Markets
6.8 Increasingly Complex Nature of Pharmaceutical Vigilance
6.9 Harmonization of International Regulations Can Lead to Cost Reductions
6.10 The Effect of the Internet and Social Media on ADR Reporting
6.11 Collaboration between the FDA and EMA
6.12 The Challenge of Obtaining High-Quality ADR Information
6.13 Linking Pharmacovigilance to Genomics and Biomarkers
6.14 Generics, Globalisation and Drug Safety

7. Research Interviews

7.1 Interview with Nina Lahanis, Vice President of Marketing and Business Development, Drug Safety Alliance, USA
7.1.1 What Activities Are Outsourced and Why?
7.1.2 Mergers, Big Data, and New Regulations – The Challenges of Pharmacovigilance in the 21st Century
7.1.3 Risk-Benefit Profiles and the Importance of Global Harmonisation
7.1.4 Social Media and Electronic Health Records – Leading Trends in Pharmacovigilance
7.1.5 The True Cost of Off-shoring
7.2 Interview with Dr Angela van der Salm, Director of Pharmacovigilance, DADA Consultancy, Netherlands
7.2.1 What Activities Are Outsourced and Why?
7.2.2 The Challenges Posed by M&A Activity and New EU Regulations
7.2.3 Heightened Awareness of Risk Management
7.2.4 Transparency and Other Trends in Pharmacovigilance
7.2.5 Actively Monitoring Drug Safety
7.3 Interview with Mark Bartlett, Co-Founder and Managing Director, Geneix, UK
7.3.1 Technological Impact on Pharmacovigilance
7.3.2 Digital Healthcare Platforms and Pharmacovigilance
7.3.3 Electronic Healthcare Records
7.3.4 Role of Pharmacogenomics in Pharmacovigilance

8. Conclusions

8.1 International Collaboration Will Increase
8.2 Pharmacogenomics Will Become Important in Drug Approval and Safety Analysis
8.3 Drug Safety Monitoring Will Become Active
8.4 Social Media Will Become a Pharmacovigilance Tool

List of Tables

Table 2.1 Pharmacovigilance Terminology in the EU and US, 2014
Table 2.2 Sample Size Required to Detect ADRs Based on Incidence, 2014
Table 2.3 Number of Phase IV Clinical Trials by Registration Date, 2004-2014
Table 3.1 Full Members of the WHO Program for Drug Safety Monitoring, 2014
Table 3.2 Global Pharmaceutical R&D Spending Forecast: Global Spending on R&D ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 3.3 Global Pharmacovigilance Spending Forecast: Global Spending on Pharmacovigilance Operations ($bn), Proportion of R&D Spending (%), Annual Growth (%), CAGR (%), 2013-2024
Table 4.1 Spending on Pharmacovigilance in National and Regional Markets: Market Size ($bn), Market Share (%), 2013
Table 4.2 Forecast Spending on Pharmacovigilance in National and Regional Markets: Spending ($bn), Annual Growth (%), CAGR (%), 2013-2018
Table 4.3 Forecast Spending on Pharmacovigilance in National and Regional Markets: Spending ($bn), Annual Growth (%), CAGR (%), 2018-2024
Table 4.4 Forecast Spending on Pharmacovigilance in National and Regional Markets: Market Shares (%), 2013-2024
Table 4.5 Adverse Drug Reactions Entered into the FAERS Database: Expedited (000s), Medwatch (000s), Periodic (000s), Total Entered (000s), Annual Growth (%), 2003-2012
Table 4.6 Adverse Drug Reactions Entered into the FAERS Database by Country of Origin: Domestic (000s), Foreign (000s), Unknown (000s), Total Entered (000s), Annual Growth (%), 2003-2012
Table 4.7 Forecast Spending on Pharmacovigilance in the US: Spending ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.8 Forecast Spending on Pharmacovigilance in the European Union: National Market Sizes ($bn), Annual Growth (%), EU Market Shares (%), CAGRs (%), 2013-2018
Table 4.9 Forecast Spending on Pharmacovigilance in the European Union: National Market Sizes ($bn), Annual Growth (%), EU Market Shares (%), CAGRs (%), 2018-2024
Table 4.10 Individual Case Safety Reports Made to the Eudravigilance Database by Nation, 2012
Table 4.11 Forecast Spending on Pharmacovigilance in Germany: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.12 Forecast Spending on Pharmacovigilance in France: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.13 Forecast Spending on Pharmacovigilance in the UK: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.14 Forecast Spending on Pharmacovigilance in Italy: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.15 Forecast Spending on Pharmacovigilance in Spain: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.16 Drug Re-examination Schedule in Japan, 2013
Table 4.17 ADRs Reported to Japanese Regulators: Domestic (000s), Foreign (000s), Healthcare Providers (000s), Annual Growth (%), 2008-2012
Table 4.18 Forecast Spending on Pharmacovigilance in Japan: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.19 Forecast Spending on Pharmacovigilance in the BRIC Nations: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2013-2018
Table 4.20 Forecast Spending on Pharmacovigilance in the BRIC Nations: Market Size ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2018-2024
Table 4.21 ADRs Reported to Chinese Regulators: ADRs Reported (000s), Annual Growth (%), 2003-2012
Table 4.22 Forecast Spending on Pharmacovigilance in China: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.23 Forecast Spending on Pharmacovigilance in Brazil: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.24 Forecast Spending on Pharmacovigilance in Russia: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.25 ADRs Reported in India Regulators: ADRs Reported (000s), Annual Growth (%), 2010-2013
Table 4.26 Forecast Spending on Pharmacovigilance in India: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 4.27 ADRs Reported to South Korean Regulators: ADRs Reported (000s), Annual Growth (%), 2003-2012
Table 4.28 Forecast Spending on Pharmacovigilance in South Korea: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024
Table 5.1 Other Pharmacovigilance Service Providers, 2014
Table 7.1 Social, Technological, Economic, and Political Factors (STEP) Affecting Pharmacovigilance, 2014

List of Figures

Figure 2.1 Lifecycle of Adverse Events for Vioxx, 1999-2004
Figure 2.2 Lifecycle of Adverse Events for Avandia, 1999-2010
Figure 2.3 Number of Phase IV Clinical Trials by Registration Date, 2004-2014
Figure 3.1 Country of Origin of ICSRs on UMC VigiBase: National Percentage of Cumulative ISCR Total (%), Aug 2013
Figure 3.2 Per Capita ISCRs Submitted to VigiBase: Number ISCR Submitted Per Million Inhabitants Per Year, Yearly Average 2008-2013
Figure 3.3 Global Pharmaceutical R&D Spending Forecast ($bn), 2013-2024
Figure 3.4 Global Pharmacovigilance Spending Forecast: Global Spending on Pharmacovigilance Operations ($bn), Proportion of R&D Spending (%), 2013-2024
Figure 3.5 Pharmacovigilance Market: Drivers and Restraints, 2013-2024
Figure 4.1 Spending on Pharmacovigilance in National and Regional Markets: Market Share (%), 2013
Figure 4.2 Forecast Spending on Pharmacovigilance in National and Regional Markets: Spending ($bn), 2013-2024
Figure 4.3 Forecast Spending on Pharmacovigilance in National and Regional Markets: Market Share (%), 2018
Figure 4.4 Forecast Spending on Pharmacovigilance in National and Regional Markets: Market Share (%), 2024
Figure 4.5 Adverse Drug Reactions Entered into the FAERS Database: Expedited (000s), Medwatch (000s), Periodic (000s), 2003-2012
Figure 4.6 Adverse Drug Reactions Entered into the FAERS Database by Country of Origin: Domestic (000s), Foreign (000s), Unknown (000s), 2003-2012
Figure 4.7 Forecast Spending on Pharmacovigilance in the US: Market Size ($bn), 2013-2024
Figure 4.8 Forecast Spending on Pharmacovigilance in European Union (EU5): National Market Sizes ($bn), 2013-2024
Figure 4.9 Individual Case Safety Reports Made to the Eudravigilance Database by Nation, 2012
Figure 4.10 Forecast Spending on Pharmacovigilance in Germany: Market Size ($bn), 2013-2024
Figure 4.11 Forecast Spending on Pharmacovigilance in France: Market Size ($bn), 2013-2024
Figure 4.12 Forecast Spending on Pharmacovigilance in the UK: Market Size ($bn), 2013-2024
Figure 4.13 Forecast Spending on Pharmacovigilance in Italy: Market Size ($bn), 2013-2024
Figure 4.14 Forecast Spending on Pharmacovigilance in Spain: Market Size ($bn), 2013-2024
Figure 4.15 ADRs Reported to Japanese Regulators: Domestic (000s), Foreign (000s), Healthcare Providers (000s), 2008-2012
Figure 4.16 Forecast Spending on Pharmacovigilance in Japan: Market Size ($bn), 2013-2024
Figure 4.17 Forecast Spending on Pharmacovigilance in BRIC Nations: National Marker Sizes ($bn), 2013-2024
Figure 4.18 ADRs Reported to Chinese Regulators: ADRs Reported (000s), 2003-2012
Figure 4.19 Forecast Spending on Pharmacovigilance in China: Market Size ($bn), 2013-2024
Figure 4.20 Forecast Spending on Pharmacovigilance in Brazil: Market Size ($bn), 2013-2024
Figure 4.21 Forecast Spending on Pharmacovigilance in Russia: Market Size ($bn), 2013-2024
Figure 4.22 ADRs Reported in India: ADRs Reported (000s), 2010-2013
Figure 4.23 Forecast Spending on Pharmacovigilance in India: Market Size ($bn), 2013-2024
Figure 4.24 ADRs Reported to South Korean Regulators: ADRs Reported (000s), 2003-2012
Figure 4.25 Forecast Spending on Pharmacovigilance in South Korea: Market Size ($bn), 2013-2024
Figure 7.1 Strengths and Weaknesses in Pharmacovigilance, 2014
Figure 7.2 Opportunities and Threats in Pharmacovigilance, 2014

掲載企業リスト

Companies Listed

Abbott Laboratories
Accenture
Accovion
Actavis
Agence française de sécurité sanitaire des produits de santé
Agencia Española de Medicamentos y Productos Sanitarios
Agenzia Italiana del Farmaco (AIFA)
Aprova
Aptiv Solutions
ARIS Global
AstraZeneca
Bayer
Brazilian Health Surveillance Agency (ANVISA)
Bristol-Myers Squibb
Capgemini
Center for Biologics Evaluation and Research
Center for Drug Evaluation and Research
Central Drugs Standard Control Organization
China Food and Drug Agency
China Food and Drug Agency (CFDA)
Chinese Ministry of Health
Cognizant Technology Solutions
Commission on Human Medicines
Committee for Medicinal Products for Human Use
Committee on the Safety of Medicine
Contergan Foundation
Covance
Crossoak Pharma
Crown Consultants
CSO Pharma Consulting
DADA Consultancy
Danish Medicines Agency
Dose Spot
Drug Safety Alliance
Dun & Bradstreet
Dutch Medicines Evaluation Board
Eli Lilly
Epidemico
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency (EMA)
European Medicines Evaluation Agency (EMEA)
European Union (EU)
Facebook
Federal Association of Thalidomide Victims
Federal Centre for Monitoring Drug Safety
Federal Institute for Drugs and Medical Devices
Federal Service on Surveillance in Healthcare and Social Development (Roszdravnadzor, Russia)
First Databank
Food and Drug Administration (US FDA)
Foresight Group International
Forest Laboratories
GB Pharma
Geneix
GlaxoSmithKline (GSK)
Handle My Health
Harten Group
HCL Technologies
ICON
iGATE Corporation
Illumina
iMED Global
Imperial Chemical Industries
INC Research
Indian Pharmacopoeia Commission
Infosys
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
inVentiv Health
IPM Safety Services
Japanese Pharmaceuticals and Medical Devices Agency
Johnson & Johnson
Kinapse
Korea Food and Drug Administration
Lindeq
Mahindra Satyam
Medicines and Healthcare Products Regulatory Agency (MHRA, UK)
MedImmune
Merck & Co.
Merck Serono
Ministero della Salute
Ministry of Food and Drug Safety (MFDS, Korea)
Ministry of Health, Labour and Welfare (MHLW, Japan)
National Agency for Safety of Medicine and Health Products
National Patient Safety Agency
NDA Group
Nhumi Technologies
Norwegian Medicines Agency
Novartis
November Research Group
Novo Nordisk
Optum
Oracle
Orbis Clinical
ParagonRX
Parexel
PatientsLikeMe
Patni Computer Systems
Paul Ehrlich Institute
Pfizer
Pharmaceutical and Medical Devices Agency (PMDA, Japan)
Pharmacovigilance Risk Assessment Committee
PharSafer
PPD
PRA International
Primevigilance
Quanticate
Quantum Solutions India
Quintiles Transnational
Ranbaxy
Roche
Sanofi
Sciformix
Serious Adverse Event Consortium (SAEC)
Servier
SGS Life Sciences
Shenyang Pharmaceutical University
State Food and Drug Agency
Sun Pharmaceuticals
Symogen
Synowledge
TAKE Solutions
Tata Consultancy Services
Tech Mahindra
Twitter
UDG Healthcare
uMotif
Unified Health System
United Biosource Company
Uppsala Monitoring Centre (UMC))
Warner Chilcott
Watson
Wipro Limited
Wockhardt
World Bank
World Health Organization (WHO)
Xendo

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。